Spyre Therapeutics: CFO Burrows Scott L sold 25,000 shares

What happened

• Burrows Scott L, CFO, exercised options to acquire 25,000 shares (17,500 on Sep 30, 2026 and 7,500 on Oct 1, 2026) at $14.50 per share for $362,500, and sold 25,000 shares in open-market transactions for aggregate proceeds of $2,261,831.
• The Form 4 also reports two entries labeled "exercise or conversion of derivative" showing 17,500 and 7,500 shares disposed at $0.00.

Key details

• Transaction dates and prices:
  • Sep 30, 2026: exercised 17,500 shares at $14.50 ($253,750) and sold 17,500 shares at a weighted average price of $89.89 for $1,573,075 (see footnotes for the per-trade price range).
  • Oct 1, 2026: exercised 7,500 shares at $14.50 ($108,750) and sold 7,500 shares across multiple transactions at weighted average prices (ranges reported in footnotes) for total proceeds of $688,756.
• Shares owned after the transactions (as described in footnotes): reporting person holds options to purchase 404,857 shares (adjusted for prior reverse split; one quarter vested Sep 1, 2024, remainder vesting monthly) and includes 33,738 RSUs that vest Sep 1, 2027.
• Footnotes of note: several sales reported as weighted average prices with per-trade ranges (F1, F3–F7); one sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F2).
• Filing date: Oct 2, 2026 (period of report Sep 30, 2026).

Why it may matter

• The Form 4 shows the insider exercised options and sold the resulting shares in open-market transactions, with some sales executed under a Rule 10b5-1 plan and several sales reported as weighted averages across multiple trade prices.
• The filing does not show why the insider traded or why the company acted.